Gilead Wins Reversal of $2.54 Bln Hepatitis C Drug Patent Verdict Gilead Wins Reversal of $2.54 Bln Hepatitis C Drug Patent Verdict

A federal judge in Delaware has overturned a jury ' s verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck& Co Inc.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news